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Ras signaling regulates osteoprogenitor cell
proliferation and bone formation
Garyfallia Papaioannou1, Fatemeh Mirzamohammadi1 and Tatsuya Kobayashi*,1
During endochondral bone development, osteoblasts are continuously differentiated from locally residing progenitor cells.
However, the regulation of such endogenous osteoprogenitor cells is still poorly understood mainly due to the difficulty in
identifying such cells in vivo. In this paper, we genetically labeled different cell populations of the osteoblast linage using stage-
specific, tamoxifen-inducible Cre transgenic mice to investigate their responses to a proliferative stimulus. We have found that
overactivation of Kras signaling in type II collagen-positive, immature osteoprogenitor cells, but not in mature osteoblasts,
substantially increases the number of their descendant stromal cells and mature osteoblasts, and subsequently increases bone
mass. This effect was mediated by both, the extracellular signal-regulated kinase (ERK) and phosphoinositide 3 kinase (PI3K),
pathways. Thus we demonstrate that Ras signaling stimulates proliferation of immature osteoprogenitor cells to increase the
number of their osteoblastic descendants in a cell-autonomous fashion.
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Bones are formed and maintained by multiple types of bone
cells.1 Mineralized bone matrix is produced by osteoblasts.
Osteoblasts produce a large amount of bone matrix proteins
including type I collagen and osteocalcin. Osteoblasts then die
or further differentiate into osteocytes that are embedded in
the bone matrix.2,3 Bone is constantly remodeled throughout
life. During this process, osteoblasts are continuously differen-
tiated from locally residing mesenchymal progenitor cells.
Thus, proliferation and differentiation of the osteoblast
progenitors need to be well coordinated to maintain adequate
bone mass and function.
However, characteristics, kinetics and regulation of such
endogenous osteoprogenitor cells are still poorly understood,
primarily due to the lack of proper tools for in vivo analysis of
such cells.
Recently, it has been shown that a subset of early osteo-
progenitor cells show a promoter activity of the type II collagen
gene (Col2a1); a lineage tracing study using Col2-creER and
Cre reporter transgenic mice in which tamoxifen injection
genetically labels Col2-positive cells shows that Col2-positive
cells include self-renewing early osteoprogenitor cells.4 Upon
lineage commitment, osteoprogenitor cells start expressing
Sp7 (Osterix; Osx).3–5 In contrast, mature osteoblasts and
their descendants can be exclusively labeled by the use
of short promoter fragments of the type I collagen gene
(Col1a1).3,6
In this study, using stage-specific, tamoxifen-inducible
Cre transgenic lines, we demonstrate that Ras signaling
regulates proliferation of Col2-positive osteoprogenitor cells
and controls bone mass, whereas Ras overactivation shows
little effect in mature osteoblasts. Thus, the difference of
responsiveness to Ras signaling discriminates differentiation
stages of cells of the osteoblast lineage.
Results
Col2-positive cells are self-renewing osteoprogenitors.
To determine the fate of osteoblast-lineage cells in different
differentiation stages, we genetically labeled cells using
stage-specific, tamoxifen-inducible Cre transgenic mice and
R26R-tdTomato Cre reporter mice. We crossed R26R-
tdTomato reporter mice7 with Cre transgenic mice expressing
tamoxifen-inducible Cre recombinase driven by a type II
collagen (Col2a1) promoter (Col2-creER),8 an osterix (Sp7;
Osx) promoter (Osx-creER),9 or a 3.2 kb-long type I collagen
promoter (Col1-creER)9 (Figure 1a). We injected a single
dose of tamoxifen into pregnant mothers at E18.5 to label
Cre-expressing cells. Tamoxifen induces Cre recombination
and subsequently tomato expression, and thus Cre-express-
ing cells as of tamoxifen injection and their descendants will
express tomato red fluorescent protein.
As recently shown in postnatal mice,4 a small number
of Col2-creER-expressing (Col2-positive) cells were labeled
in the bone marrow 2 days after tamoxifen injection
(Figures 1b and e, Supplementary Figures S1A, S1D). Over
time, these cells produced a significant number of descen-
dants that differentiated into bone stromal cells, osteoblasts
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and osteocytes (Figures 1c,d and f-h, Supplementary Figures
S1B, S1C, S1E, S1F).
As expected, Osx-creER-expressing (Osx-positive) and
Col1-creER-expressing (Col1-positive) cells were abundantly
present on bone surface at early time points after tamoxifen
injection. In these models, numbers and localization patterns
of RFP-labeled cells appeared relatively constant during the
1-month chase period (Figures 1i-n, Supplementary Figures
S1G-S1N). Col1-creER-expressing cells and their descen-
dants are mainly osteoblasts and osteocytes (Figure 1n,
Supplementary Figure S1N), whereas Osx-creER labels
stromal cells, osteoblasts and osteocytes (Figure 1k, Supple-
mentary Figure S1J). Tamoxifen injection into Osx-creER at
E18.5 does not label cells in the secondary ossification center
(Supplementary Figure S1H). Because the secondary ossifi-
cation center is not yet formed at E18.5, this finding suggests
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that Osx-positive cells and their descendants in the primary
ossification center unlikely migrate into the secondary
ossification center to serve as a source of osteoblasts.
Expression of an oncogenic Kras in Col2-positive cells
increases the number of their descendant cells and
trabecular bone mass. Mechanisms that regulate prolifera-
tion, differentiation and maintenance of endogenous osteo-
progenitor cells in bone are still largely unknown. The recent
finding that a self-renewing endogenous osteoprogenitor
population can be genetically labeled using Col2-creER and
R26R-tdTomato transgenic mice provided an opportunity to
investigate the regulation of osteoprogenitor cells in vivo.
One of major regulators of cell proliferation is the Ras
signaling pathway. The small GTPase, Ras, mediates the
extracellular proliferative stimuli to downstream intracellular
signaling molecules, including the extracellular signal-
regulated kinase (ERK) and phosphoinositide 3 kinase
(PI3K) pathways, to stimulate cell cycle progression. Thus,
we hypothesized that Ras-mediated signaling pathways might
regulate osteoprogenitor cell proliferation.
In order to study the effect of overactivation of Ras signaling
in osteoprogenitor cells in vivo, we expressed an active form of
Kras (KrasG12D)10 in Col2-positive cells that were simulta-
neously labeled with Tomato red fluorescent protein using
Col2-creER transgenic mice. Expression of KrasG12D and
Tomato was induced at E18.5 by a single dose of tamoxifen
injection into pregnant mothers.
Two days after tamoxifen injection, only small numbers of
Tomato-expressing cells were found in the meta-
physeal region of both KrasG12D-positive and negative mice
(Figures 2a-d). However, 1 month later Tomato-positive cells
were significantly more abundant in KrasG12D-positive mice
than in KrasG12D-negative mice (Figures 2e and f). The
increase in Tomato-positive cells in KrasG12D-positive mice
involved osteocytes, osteoblasts as well as stromal cells
(Figures 2g and h). Hematoxylin-eosin (H/E) staining of tibia
sections showed a striking increase in trabecular bonemass in
mice with Kras activation in Col2-positive cells and their
descendants (Figures 2i and j). Littermates lackingCre or Kras
were used as controls, and they received the same amount
of tamoxifen as the mutant mice. KrasG12D mice without
Cre recombination had the same bone phenotype as wild-type
mice. In the absence of tamoxifen there were no overt
bone phenotypes in mutant mice (Supplementary Figures
S2A-S2B).
A similar phenotype was observed in the humerus as in
the tibia upon Kras activation in Col2-postive cells (Supple-
mentary Figures S2C-S2D). Microcomputed tomography
(μCT) analysis showed that there was a significant increase
in the bone volume fraction, trabecular number and trabe-
cular thickness and a decrease in trabecular separation
(Figures 2k-p). The cortical bone parameters were
unchanged. There were no overt changes in tartrate-resis-
tant acid phosphatase (TRAP) staining (Supplementary
Figures S2I-S2J), suggesting that bone-resorbing osteoclasts
were not affected.
In addition to the increased bone mass, H/E staining
revealed a substantial increase in the number of stromal cells
between the trabeculae (Figures 3a and b, Supplementary
Figures S2E, S2F, and Figure 4m). These stromal cells
weakly expressed Col1a1 while they were negative for the
mature osteoblast marker, Bglap that encodes osteocalcin
(Figures 3c-f).
As expected, KrasG12D expression increased the number of
cells that are positive for phosphorylated ERK1/2 (p-ERK)
over time (Figures 3g-j). The PI3K pathway, another important
pathway downstream of Kras, was also found activated in the
stromal cells of KrasG12D mice, as demonstrated by the
increase in phosphorylation of Akt (p-Akt) (Figures 3k and l).
To assess the proliferation of stromal cells, BrdU assay was
performed. As expected, the BrdU labeling index of the
stromal cell population in the KrasG12D mouse was increased
at postnatal day P10 (Figures 3m-q).
Overactivation of Ras signaling influences cell survival. In
order to test whether oncogenic Ras expression affects cell
survival, a cell death assay (TUNEL assay) was performed to
compare the apoptosis rate in the primary spongiosa of
KrasG12D mice and wild-type mice (Supplementary Figures
S3E-S3G). Although a tendency for increased apoptosis in
KrasG12D mice was observed, the difference in cell death
signals counted was not statistically significant (control versus
mutant: 11±4.6 versus 19.7± 4 P=0.07, n=3 each).
This suggests that the increase in proliferation of stromal cells
is the dominant mechanism for bone increase in the
KrasG12D mice.
We then wanted to address the question whether the effect
of Kras overexpression in Col2-positive cells was age-specific.
Activating Kras at P20 in Col2-positive cells caused a
similar increase in bone and stromal cells, suggesting that
Col2-positive cells are continuously present and serve as
Figure 1 The fate and localization of bone-forming cells: Col2-, Osx- and Col1-positive cells during bone development (see also Supplementary Figure S1). (a) Experimental
design. R26R-tdTomato reporter mice were crossed with transgenic mice expressing creER under the control of Col1, Osx and Col2 promoters. A single dose of tamoxifen
(0.1 mg/g) was intraperitoneally (i.p.) injected into pregnant mothers at E18.5. (b-d) Hematoxylin/eosin-stained paraffin sections of the proximal metaphysis of the tibia at indicated
ages (P= postnatal day, TB= trabecular bone, BM= bone marrow, HZ= hypertrophic chondrocyte zone). (e-g) Fluorescent images of the tibia of B-D (×10). Blue:Dapi; Red:
Tomato red fluorescent protein. (h) A cryosection (×20 magnification) of the secondary ossification center in the Col2-creER;R26Rtomato mouse tibia at P28. Tomato-labeled cells
are observed on the bone surface (osteoblasts; thick arrow), inside of the bone matrix (osteocytes; thin arrow), and in the bone marrow (dotted arrow). (i-j) Cryosections
(×10 magnification) of the Osx-creER;R26Rtomato mouse tibiae at indicated ages. Blue, DAPI; red, Tomato red fluorescent protein. (k) Cryosection (×10 magnification) of the Osx-
creER;R26Rtomato mouse tibia bone marrow at P28. Blue: DAPI; red: Tomato red fluorescent protein; thick arrow: osteoblasts; thin arrow: osteocytes; dotted arrow: stromal cells.
(l-m) Cryosections (×10 magnification) of the Col1-creER;R26Rtomato mouse tibia pulsed with tamoxifen at age E18.5. Tomato (red fluorescent protein) labeled the Col1-positive
cells at age E18.5 and cell fate was chased at ages P1.5 and P28. (n) Cryosection of Col1-creER;R26Rtomato mouse tibia showing the secondary ossification center
(×20 magnification) at P28. Blue, DAPI; red, Tomato red fluorescent protein. thin arrow: osteocytes; thick arrow: osteoblasts. No tomato-positive cells were found in the bone
marrow. n= 5 mice per group
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osteoprogenitor cells in postnatal bone (Supplementary
Figures S3A-S3D).
MAPK and PI3K are the main signaling pathways
responsible for the increase in bone with Kras activation.
Kras signals mainly through the mitogen-activated protein
kinase (MAPK) and PI3K pathways.11 In order to investigate
whether activation of these signaling pathways was
responsible for the bone phenotype of Kras mice, we
pharmacologically inhibited the ERK and PI3K pathways.
We injected U0126, an inhibitor of ERK kinase (MEK), or
LY294002, a PI3K inhibitor from E18.5 through P21. Both
MEK inhibition (Figures 4h and k) and PI3K inhibition
(Figures 4i and l) partially, but significantly, rescued the
phenotype in Col2-creER; KrasG12D mice injected with
tamoxifen at E18.5, as demonstrated by the decreased
stromal cell number and trabecular bone (Figure 4h, i, k, l, m
and comparison with figures 4g, j). In both MEK inhibition and
PI3K inhibition, their downstream molecules (p-ERK and
p-Akt signals respectively) were suppressed after the
treatment with inhibitors (Supplementary Figures S4A-S4F).
These findings suggest that activation of both MAPK and
PI3K pathways contribute to the bone phenotype of
KrasG12D mice.
Figure 2 Expression of KrasG12D in Col2-positive cells at E18.5 increases the number of their descendants and the trabecular bone mass (see also Supplementary
figure S2). (a-d) Tomato-positive cells in the tibial metaphysis of Col2-creER;R26Rtomato mice with wild-type Kras (a, c) and KrasG12D (b,d) at P1.5. Mice were treated with
tamoxifen at E18.5. A,B: × 4 magnification. c,d: × 20 magnification. Blue, DAPI; red, Tomato red fluorescent protein. Dotted lines indicate the borders of tibia. The middle dotted
line indicates the border between growth plate and primary spongiosa (trabecular bone). Magnifications of primary spongiosa of a and b are shown in c and d respectively (n= 3).
(e-h) Tomato-positive cells in the tibial metaphysis of Col2-creER;R26Rtomato mice with wild-type Kras (e,g) and KrasG12D (f,h) at P28. The mice were treated with tamoxifen at
E18.5. E,F: × 4 magnification. g,h: × 20 magnification. Blue, DAPI; red, Tomato red fluorescent protein; arrow: osteocytes; double arrow: osteoblasts; dotted arrow: stromal cells
(n= 4). (i-j) Hematoxylin/eosin-stained paraffin sections of tibias at P28 from Col2-creER mice with wild-type Kras (i) and KrasG12D (j) after Kras activation at E18.5
(×4 magnification). Mice harboring KrasG12D show increased trabecular bone with a minimal effect in the growth plate structure (n= 8). (k-l) MicroCT pictures of tibias at P28 from
Col2-creER mice with wild-type Kras (k) and KrasG12D (l) after Kras activation at E18.5. (m-p) Graphs showing comparisons of bone volume fraction (m), trabecular number (n),
trabecular thickness (o) and trabecular separation (p) measured by microCT in mice with wild-type Kras or KrasG12D at P28 (n= 3 and n= 4 for mutant and control groups,
respectively)
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KrasG12D expression in Col1-positive cells does not
increase stromal cells or bone mass. Next, we investi-
gated the effect of Kras activation in lineage-committed
osteoblasts. We used Osx-creER and Col1-creER to target
osteoblasts in early and late differentiation stages, respec-
tively. A single dose of tamoxifen was injected into mice
at E18.5 to induce expression of KrasG12D and Tomato in
Osx-positive or Col1-positive cells.
Figure 3 Activation of Kras oncogene in Col2 cells at perinatal age increases stromal cell numbers (see also Supplementary figure S3). (a-b) Hematoxylin/eosin-stained
paraffin sections showing the stromal cells between the trabeculae in P28 mice (secondary spongiosa) control (a) and KrasG12D (b) after Kras activation at E18.5. × 40
magnification. (c-f) In situ hybridization for collagen 1 (Col1 ISH) (c,d) and osteocalcin (Oc ISH) (e,f) in the secondary spongiosa of P28-old mice control (c,e) or KrasG12D
(d,f) after tamoxifen injection at E18.5. Stromal cells are not stained for these markers. Black arrows, osteoblasts; red asterisks, stromal cells. (g-j) Immunohistochemistry for
p-ERK at P1.5 (g,h) and P10 (i,j) in the tibia secondary spongiosa of control (g, i) and KrasG12D (h, j) after tamoxifen injection at E18.5. Arrows show representative cells stained
with anti- p-ERK. (k-l) Immunohistochemistry for p-Akt at P10 in the tibia secondary spongiosa of control (k) or KrasG12D (l) after tamoxifen injection at E18.5. Arrows show
representative cells stained with anti- p-Akt antibody. (m-p) BrdU (Bromodeoxyuridine) labeling of proliferating cells in the metaphysis of mice (tibia) control (m,o) and KrasG12D
(n,p) at P10 after Kras activation at E18.5. BrdU-positive cells are stained brown. (q) The BrdU index, calculated as the percentage of BrdU-labeled stromal cells, was
significantly increased upon KrasG12D activation. Stromal cells were defined as the non-hematopoietic cells that were not attached to the bone matrix. Data are represented as
mean±S.E.M.; n= 3, *P= 0.002
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Figure 4 The MAPK and PI3K pathways are responsible for the increase in bone. (a-f) Hematoxylin/eosin-stained paraffin sections of tibias from Col2-creER or KrasG12D
(control) mice at P21 (tamoxifen injection at E18.5) treated with vehicle (methylcellulose) (a,d), MEK inhibitor (U0126; 5 mg/kg) (b,e), or PI3K inhibitor (LY294002 100 mg/kg) (c,f).
(g-l) Hematoxylin/eosin-stained paraffin sections of tibias from Col2-creER;KrasLSL-G12D/+ mice at P21 after tamoxifen injection at E18.5 (g,j), with MEK inhibitor U0126 injections
(h,k) or PI3K inhibitor LY294002 injections (i,l). After MEK or PI3K inhibition, mice harboring KrasG12D show reduced trabecular bone and significantly smaller number of stromal
cells than the vehicle-injected mutants. a,b,c, g, h, i: × 4 magnification. d, e, f,j, k, l: × 40 magnification. (m) Stromal cell counts in control and mutant mice injected with vehicle or
MEK inhibitor or PI3K inhibitor. Data are represented as mean±S.E.M.; n= 3, *Po0.05. Spindle-shaped cells, not attached to the bone matrix were counted in the center of
secondary spongiosa in × 20 magnification
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KrasG12D expression in Osx-positive cells caused a pheno-
type similar to, but somewhat milder than, that of the Col2-
creER model (Figures 5a-d). Tomato-positive Osx-positive
cells and their descendants were found in both bone and
stromal compartments (Figures 5e-h).
In contrast, activating Kras in the Col1-positive cells
caused no significant changes in bone or stromal cells at
P28 (Figures 5i-l), despite that KrasG12D expression signifi-
cantly increased ERK phosphorylation in osteoblasts
(Supplementary Figures S5A-S5D). Consistent with this
result, there was no significant increase in tomato-positive
Col1-positive cell descendants (Figures 5m-p). These results
suggest that Ras activation has no stimulatory effect in
differentiated osteoblasts.
Discussion
In this study, we investigated the role of Ras signaling in
three different cell populations of the osteoblast lineage,
that is, Col2-, Osx- and Col1-positive cells, during bone
development.
Kras overactivation in Col2-positive or Osx-positive cells in
bone at E18.5 led to a significant increase in number of their
descendant cells and trabecular bone mass. In contrast, Kras
overactivation in Col1-positive cells did not show significant
effects in cell number or bonemass, suggesting that Col2- and
Osx-positive cells, but not Col1-positive cells, include pro-
liferative osteoblast progenitors. This study also demonstrates
that Ras signaling is an important positive regulator of
proliferation of early osteoprogenitor cells.
Multiple signaling molecules, including receptor tyrosine
kinases (RTKs),12 have been implicated in regulation of prolifera-
tion and survival of bone progenitor cells.13,14 Kras, a small
GTPase activated by RTKs, triggers downstream effector path-
ways, suchas theMAPK (mitogen-activating protein kinase), PI3K
(Phosphatidylinositol 3'-kinase) and Ral-GEF (Ras-like small
GTPases) pathways, to regulate cellular functions including
proliferation, differentiation and apoptosis.15 Multiple Ras-
activating molecules, including fibroblast growth factors (FGFs)/
FGF receptors,16 epidermal growth factors (EGFs)/ EGF recep-
tors17 and insulin-like growth factors (IGFs) and their receptors,18
have been implicated in regulating bone development.
Figure 5 Overexpression of Kras in Osx cells perinatally causes a milder increase in bone and stromal cells, while in Col1 cells it has no effect (see also Supplementary
figure S4). (a-b) Hematoxylin/eosin-stained paraffin sections of tibias from P28-old Osx-creER mice control (a,c) and KrasG12D (b,d) after Kras activation at E18.5. a,b: × 4
magnification, c,d: × 40 magnification. (e-h) Cryosections showing tomato-positive cells in P28-old Osx-creER mice control (e,g) and KrasG12D (f,h) after tamoxifen injection at
E18.5. e,f × 4 magnification; g,h × 10 magnification. Blue, DAPI; red, Tomato red fluorescent protein. (i-l) Hematoxylin/eosin-stained paraffin sections of tibias from P28
Col1-creER mice control (i,k) and KrasG12D (j,l) after tamoxifen injection at E18.5. i,j: × 4 magnification, k,l: × 40 magnification. (m-p) Cryosections showing tomato-positive cells
in P28 Col1-creER mice with wild-type Kras (m,o) and KrasG12D (n,p) after tamoxifen injection at E18.5.m,n: × 4 magnification, o,p: × 20 magnification. Blue, DAPI; red, Tomato
red fluorescent protein. For both the Osx model and Col1 model n= 5 mice per group
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Ras signaling has been shown to increase stem/progenitor
cell proliferation in multiple tissues. Kras activation has been
shown to increase proliferation of bone marrow hematopoietic
cells.19–21 Additionally an oncogenic Kras increases prolifera-
tion of mouse embryonic fibroblasts22 and facilitates self-
renewal of a subtype of alveolar stem cells.23 Additionally Ras
activation by partial loss of Nf1 gene in osteoprogenitor cells
was found to increase proliferation and cause premature
apoptosis.24 In the present model apoptosis was not found
significantly increased; thus, we conclude that the increase in
proliferation is the dominant effect of Kras activation in
osteoprogenitor cells.
However, there have been relatively limited studies that
investigate the role of Ras-MAPK signaling pathway in
osteoblast progenitor cells in bone in vivo. It has been shown
that the ERK signaling pathway, a major downstreammediator
of Ras, in mesenchymal progenitor cells promotes osteoblast
differentiation and bone formation during early skeletal
development.25 Nonetheless, the proliferative effect of ERK
signaling specifically in osteoprogenitor cells has not been
addressed. In another study in which a dominant negative or a
constitutively active MEK1 was expressed in relatively mature
osteoblasts, ERK signaling stimulated osteoblast differentia-
tion without obvious changes in proliferation.26 The result of
this study is consistent with our finding that Kras overactivation
in Col1-positive mature osteoblasts had little effect in bone
mass or stromal cell proliferation. In our study, we found
that ERK inhibition significantly reduced the number of stromal
cells in KrasG12D mice, suggesting that ERK overactivation is,
at least in part, responsible for the proliferative effect of
KrasG12D expression in Col2-positive osteoprogenitors. We
also found that PI3K inhibition partially reduced stromal cells
and partially rescued the bone phenotype caused by KrasG12D
expression. Thus our study demonstrates that in addition to
the ERK pathway, the PI3K pathway also plays an important
role in osteoprogenitor proliferation.
To investigate the pathways downstreamof Kraswe injected
mice with small molecule inhibitors of MEK and PI3K. With
the dosage and timeframe of these experiments we did not
observe significant changes in the mouse body size or
condition. The wild-type control mice injected with MEK
inhibitor showed no appreciable changes in bone.
Over-expression of active Kras in Col2-Cre-positive cells
is not physiologically present during development, and there-
fore our findings do not necessarily demonstrate that
endogenous Ras signaling is a physiologic regulator of
osteoprogenitor cells. Nevertheless, using this system, we
are able to show that Col2-positive or Osx-positive cells, but
not Col1-positive cells include osteoprogenitor cells that can
be discriminated by responses to Ras signaling. Additionally
these experiments show that MAPK and PI3K pathways
activation in the above cell populations can activate bone
formation.
The loss of balance between bone formation and
bone resorption results in osteoporosis.27 Since treatment
options to increase bone formation are currently limited,28
novel bone anabolic therapies are highly desired. Our
study shows that stimulating Ras signaling in endogenous
osteoprogenitor cells can be a valid treatment strategy for
osteoporosis.
Materials and Methods
Mice. Col2a1-creERT2,8 Osx-creERT2,3 Col1-creERT2,9 and Cre-dependent
Kras transgenic, loxP-stop-loxP-KrasG12D10 mice have been described elsewhere.
The Cre reporter, Rosa26-loxP-stop-loxP-tdTomato mice were acquired from
Jackson Laboratory (Bar Harbor, ME, USA).7 All procedures were conducted in
compliance with the Guideline for the Care and Use of Laboratory Animals
approved by Massachusetts General Hospital’s Institutional Animal Care and Use
Committee (IACUC). Mice were in a mixed genetic background. Comparisons were
made between littermates. Tamoxifen injections were given i.p. at a dose of 0.1 mg/
g to pregnant females as described elsewhere.4
Histology. For histological analysis mice were dissected, fixed in 10% formalin
overnight and decalcified in 10% EDTA for a period ranging from 1 to 14 days,
depending on the age of the mice. For H/E staining, BrdU staining, immunohisto-
chemistry and in situ hybridization, samples were paraffin processed and cut. For
fluorescent reporter analysis decalcified samples were cryoprotected in 30%
sucrose/ phosphate buffer saline (PBS) solutions then in 30% sucrose/PBS:OCT
(1:1) solutions, each overnight at 4 °C. Samples were embedded in OCT compound
(TissueTek, Sakura, Torrance, CA, USA) and transferred to dry ice to solidify OCT.
Samples were cryosectioned at the thickness of 15 μm using a cryostat (Leica
CM1850). Nikon Eclipse E800 microscope was used for imaging. Images were
merged with Spot Advanced Software.
Immunohistochemistry and in situ hybridization. Immunohisto-
chemistry analysis for phosphorylated ERK (phospho-ERK) was performed
as previously described using the Perkin Elmer TSA biotin system kit.29 The
primary antibody directed against phospho-p44/42 (ERK1/2) (Cell Signaling,
Danvers, MA, USA, catalog number:#43700) was diluted 1:300 and the secondary
biotinylated anti-rabbit antibody (Vector, Burlingame, CA, USA, catalog number
#BA1000 ) was diluted 1:300. Anti p-Akt (Cell Signaling, catalog number #2965)
antibody was diluted 1:500. ISH for type 1 collagen and osteocalcin was performed
according to published protocols.30 For all immunostaining experiments, samples
from three mice per group were analyzed.
Cell proliferation assay. For BrdU labeling 50 μg of BrdU per gram of body
weight was intraperitoneally injected into mice 2 h before euthanasia. BrdU was
detected using the BrdU in situ staining kit (invitrogen, Waltham, MA, USA). The
BrdU labeling index was calculated as the ratio of BrdU-positive nuclei over total
nuclei of stromal cells of the metaphyseal tibia.
TRAP staining. Slides were deparaffinized and rehydrated. TRAP reagent
consisted of 6 ml 50 mM tatrate in acetate buffer (PH 5.0), 0.5 mg Naphthol As-Mx,
50 μl N,N dimethylamide and 3 mg fast red violet LB. TRAP reagent was added for
5–10 min and once satisfactory color was observed, slides were washed with water
and then with PBS. At the end the slides were mounted with water-based medium.
Cell death assay (TUNEL assay). Cell death was evaluated on sections
using an in situ cell death detection kit (Roche, Branford, CT, USA) according to the
manufacturer’s instructions.
MicroCT analysis. A high-resolution desktop micro-tomographic imaging
system (μCT40, Scanco Medical AG, Basserdorf, Switzerland) was used to assess
trabecular and cortical in the proximal metaphysis and diaphysis of the tibia,
respectively. Scans were acquired and analyzed as previously described.31 Image
acquisition and analysis were performed according to the JBMR guidelines for the
use of μCT in rodents.32
To assess the trabecular architecture, transverse CT slices were evaluated in a
1500 μm (150 slices) region beginning 750 μm below the proximal growth plate and
extending distally. The trabecular bone region was identified by semi-manually tracing
with the assistance of an auto-thresholding software algorithm. A mineral density
threshold of 225 mgHA/cm3 was used for all images to segment bone from soft tissue.
Rescue experiments- inhibitors. The MEK1 inhibitor (U0126) and the
PI3K inhibitor (LY294002) were purchased from Selleckchem (Houston, TX, USA).
Inhibitors were first dissolved in DMSO according to the manufacturer’s instructions,
then diluted into PBS, and injected daily into pregnant as well as nursing mothers
intraperitoneally from E18.5 through P9.5. Subsequently, the inhibitors were injected
to pups. MEK inhibitor was injected at a dose of 5 mg/kg per day. PI3K inhibitor was
injected at a dose of 100 mg/kg four times a week.
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